

Press release

Paris, le 5 décembre 2025

Kimialys raises €3.6 million to accelerate its commercialisation and scale-up to industrial production.

Kimialys, a company that specializes in the detection and characterization of biological molecules, has reached a key milestone in its development thanks to a €3.6 million Series A fundraising round. This operation is led by Relyens Innovation Santé, advised by Turenne Capital, with the participation of new investors, including the family offices Octalfa and Evolem, as well as several well-known business angels in the industry, alongside long-standing investors Odiem Capital, BADGE, and Angels Santé.

Founded in 2020 by Cyril Gilbert and Claude Nogues, Kimialys develops and commercializes a technological platform based on an innovative chemical approach for modifying surfaces used for *in vitro* diagnostics and analysis (nanoparticles, biochips, and electrodes).

At the heart of this innovation lies the patented K-One technology, the result of more than ten years of research at the CNRS and ENS Paris-Saclay, led by Kimialys' co-founder Claude Nogues. Specifically designed for nanoparticles and planar gold surfaces, K-One offers a dual advantage: First, precise control of ligand (biomolecule) orientation, density, and distribution on the surface. Second, it protects against non-specific interactions, thereby improving the sensitivity and reliability of tests.

Kimialys offers a range of products based on this proprietary technology, structured around three complementary areas to meet the needs of the pharmaceutical and diagnostics industries. The company supplies modified gold nanoparticles, which offer better performance than conventional nanoparticles for diagnostic testing and protein and antibody extraction in pharmaceutical research. Kimialys also offers chip functionalization services and provides analytical services using these chips in surface plasmon resonance (SPR) instruments, a routine technique in drug discovery. These offerings address a common objective: opening new possibilities for biomolecule detection and characterization to help the industry meet current challenges in both innovative diagnostics and therapeutics.

This funding will enable Kimialys to finalize the industrialization of its processes, including scaling up its production capacity, developing an initial catalogue of ready-to-use kits, and intensifying its commercial efforts internationally.



Claire Poulard, Investment Director at Turenne Santé: "Kimialys has demonstrated the effectiveness of its K-One technology in improving the performance of current diagnostic tests. This breakthrough also paves the way for new applications that were previously inaccessible due to technological barriers. We are proud to support Kimialys in the development of its platform and the spreading of this disruptive innovation."

Gabriel Festoc, former President of Polyplus and Board Member: "After a more than encouraging start, Kimialys will be able to take a major step forward with this very timely funding round to finance the new industrial and commercial investments required. K-One technology represents a real breakthrough in diagnostic testing performance and has the potential to become the industry standard. I am very pleased to be part of this new phase, alongside the other board members and investors."

Cyril Gilbert, CEO of Kimialys: "This funding round is a key milestone in Kimialys' industrial development: it will enable us to finalize our patented gold nanoparticle production line, accelerate the adoption of our technology through increased sales and marketing investment, and strengthen the team to establish ourselves as a leading innovative industrial company in drug discovery and diagnostics R&D. The increased commitment from healthcare-specialized investors with deep knowledge of our industry, alongside our long-standing backers, is doubly positive: it is both a strong signal of confidence to our current customers and partners, and the assurance of optimal strategic support for the next stages of our growth."

PARTICIPANTS

Investors

Turenne Santé – Claire Poulard, Robin Pumo; **Octalfa** – Julien Alberici; **Odiem Capital (Go Capital)** – Hervé Bachelot Lallier

Legal advice and audit

Chammas & Marcheteau – Stéphanie Bréjaud, Jeanne Cormerais

Financial audit consulting

Arthaud & Associés – Julia Dumontet

PRESS CONTACTS

Delphine Granier – Turenne Groupe

dgranier@turennecapital.com

+33 6 33 05 48 50

Jérémie Spay – Relyens

jeremie.spay@relyens.eu

+33 6 45 43 76 45



ABOUT KIMIALYS

Kimialys provides consumables and services in the field of biomolecule detection and characterization for R&D laboratories involved in drug discovery and diagnostic test development. Located at Paris Biotech Santé (Cochin Hospital, Paris) and employing more than 20 people, the company enables biotech, pharmaceutical, and diagnostic firms around the world to develop tomorrow's therapies and diagnostic tests, using its patented surface functionalization technology. With more than 80% of its current sales coming from exports, Kimialys aims to become a key global supplier in the sector. Learn more at: <https://www.kimialys.com/>

ABOUT RELYENS HEALTHCARE INNOVATION

At Relyens, we are much more than just an insurer; we are risk managers. Managing, preventing, and insuring risks is the commitment of our 1,200 employees to more effectively protect healthcare providers and communities across Europe. Working alongside them, we act and innovate to promote ever safer public-interest services for all. Created in May 2014, Relyens Innovation Santé is our investment vehicle specializing in healthcare innovation capital, advised by Turenne Santé. Focused on disruptive technologies and medical research, Relyens Innovation Santé supports innovative companies in the healthcare sector (medtech, diagnostics, e-health, and biotechnology). In line with Relyens' mission, its investments pave the way for sustainable practices and solutions, contributing to a safe and reliable healthcare system for the benefit of patients.

www.relyens.eu

ABOUT TURENNE SANTÉ AND TURENNE GROUP

Turenne Santé is the healthcare investment arm of Turenne Groupe, France's leading independent small-cap private equity firm, which has been supporting entrepreneurs across the country for 25 years in their innovation, development, and succession and ownership transition projects.

With more than €2 billion in assets under management and over 300 companies in its portfolio, Turenne Groupe relies on strong sector expertise through dedicated teams in healthcare, engineering, and environmental services. It also leverages specialized expertise, including debt funds and funds with enhanced ESG criteria.

With a nationwide presence through eight regional offices (Paris, Lille, Lyon, Marseille, Nice, Bordeaux, Nantes, and Montpellier) and regional funds, Turenne Groupe has 85 employees, half of whom are region-based.

A purpose-driven company since 2023 and wholly owned by its employees, Turenne Groupe actively supports its portfolio companies in their ESG initiatives. The Turenne Santé team comprises 14 investors fully dedicated to healthcare, managing healthcare funds totaling €500 million and having already completed 51 investments and 24 exits. Turenne Groupe and the Turenne Santé team also finance and operate the Béatrice Denys Foundation, which awards grants to medical research projects.

www.turennecapital.com



ABOUT BUSINESS ANGELS FROM GRANDES ECOLES (BADGE)

Created in 2004, the Business Angels des Grandes Écoles Association is one of the leading business angel networks in France. Its members, who have recognized professional experience, participated in 29 funding rounds in 2024, raising €4.1 million. Since 2005, BADGE has financed 239 companies for more than €55 million overall, which — through leverage from other funding sources — has generated over €140 million in additional capital for these companies.

<https://business-angels.info/>

Press contact: Corentin Gaudelot – General Delegate
corentin.gaudelot@business-angels.info – 01 42 22 67 35

ABOUT ANGELS SANTE

Angels Santé is Europe's leading network of business angels dedicated to human and animal health. Since its creation in 2008, it has been supporting innovative startups in biotech, medtech, and digital health. Its strength lies in its network of expert healthcare investors, who have the expertise to provide smart money to carefully selected startups, bringing them capital and guidance to support their launch and development.

www.angelssante.fr

Contact: info@angelssante.fr